NKTR - Company ID 0000906709
NEKTAR THERAPEUTICS (NKTR) reported revenue of $55.23M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $55.23M | -43.9% |
| FY 2024 | $98.43M | +9.2% |
| FY 2023 | $90.12M | -2.1% |
| FY 2022 | $92.06M | -9.7% |
| FY 2021 | $101.91M | -33.4% |
| FY 2020 | $152.91M | +33.4% |
| FY 2019 | $114.62M | -90.4% |
| FY 2018 | $1.19B | +287.8% |
| FY 2017 |
NEKTAR THERAPEUTICS (NKTR) reported revenue of $55.23M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, NEKTAR THERAPEUTICS's revenue declined from $71.48M to $55.23M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $307.71M |
| +86.0% |
| FY 2016 | $165.44M | -28.3% |
| FY 2015 | $230.78M | +15.0% |
| FY 2014 | $200.71M | +34.8% |
| FY 2013 | $148.92M | +83.4% |
| FY 2012 | $81.19M | +13.6% |
| FY 2011 | $71.48M | - |